Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 323 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR The future of research: meet three of our scientists working on... December 13, 2022 Can mRNA Vaccines Help Treat Cancer? January 20, 2022 Volunteering with Pride: Brett’s award-winning involvement with Cancer Research UK June 15, 2023 Handmade Artisan Gifts For Under $30 November 22, 2021 Load more HOT NEWS Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition... Workout Wednesdays – Leg Exercises Part 3 Young Mom With Metastatic Breast Cancer Travels To Mexico For Alternative... FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer...
